

bs-2729R**[Primary Antibody]****ULBP2 Rabbit pAb****BioSS**
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

— DATASHEET —

Host: Rabbit	Isotype: IgG	Applications: WB (1:500-2000) ELISA (1:5000-10000)
Clonality: Polyclonal		
GeneID: 80328	SWISS: Q9BZM5	Reactivity: (predicted: Human, Cow)
Target: ULBP2		
Immunogen: KLH conjugated synthetic peptide derived from human ULBP2: 101-200/246.		
Purification: affinity purified by Protein A		Predicted MW.: 22 kDa
Concentration: 1mg/ml		Subcellular Location: Cell membrane
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: ULBP2 is a human ligand for the NKG2D receptor, together with at least ULBP1 and ULBP3. ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. The interaction with UL16 blocks the interaction with the NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system UL16 also causes ULBP2 to be retained in the ER and cis-Golgi apparatus so that it does not reach the cell surface. ULBP2 is expressed in various types of cancer cell lines and in the fetus, but not in normal tissues.		

— SELECTED CITATIONS —

- **[IF=6.38]** Shi et al. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. (2016) Cancer.Let. 373:45-56 **WB ;Human.** 26805759
- **[IF=5.6]** Wanze Zhang. et al. Novaferon gene modification promotes NK92 cell anti-tumor activity. INT IMMUNOPHARMACOL. 2023 Sep;122:110613 **WB ;Human.** 37421776